| Quality assessment | Effect | Quality | ||||||
|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Pooled effect (95% CI) | |
| Hospital mortality (assessed with: no. of patients dying in hospital) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | OR 1.33 (0.73 to 2.42) |
⨁⨁⊝⊝ LOW |
| 1 | observational studies | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | OR 1.07 (1.00 to 1.14) |
⨁⨁⨁⨁ HIGH |
| 30 day mortality (follow-up 30 days; assessed with: no. of patients dying within 30 days) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | HR 1.03 (0.89 to 1.19) |
⨁⨁⊝⊝ LOW |
| 30 day mortality (follow-up 30 days; assessed with: no. of patients dying within 30 days) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | HR 0.74 (0.42 to 1.3) |
⨁⨁⊝⊝ LOW |
| 30 day mortality (follow-up 30 days; assessed with: no. of patients dying within 30 days) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | HR 1.10 (0.6 to 2.02) |
⨁⨁⊝⊝ LOW |
| Avoidable adverse events (assessed with: bleeding complications) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | OR 1.47 (0.97 to 2.23) |
⨁⨁⊝⊝ LOW |
| Avoidable adverse events (follow-up 30 days; assessed with: MACE (death, recurrent MI, target vessel vascularisation)) | ||||||||
| 1 | observational studies | no serious risk of bias | no serious inconsistency | serious1 | serious2 | none | HR 0.81 (0.54 to 1.22) |
⨁⨁⊝⊝ LOW |
Downgraded by 1 increment if the majority of evidence included an indirect population or 2 increments if the majority of the evidence included a very indirect population.
Downgraded by 1 increment if the confidence interval crossed the null line.
From: Chapter 41, Cost-effectiveness analyses
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.